Romiplostim N01 for Platelet Recovery After Haploidentical HSCT

This is a prospective, randomized, controlled clinical study designed to evaluate the efficacy and safety of Romiplostim N01 in promoting platelet engraftment after haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT) in patients with hematologic malignancies. A total of 130 patients who undergo haplo-HSCT for acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or other hematologic malignancies will be enrolled and randomized 1:1 into a treatment group and a control group. The treatment group will receive Romiplostim N01 subcutaneously once weekly at a sta

Trial Details

NCT ID
NCT07321626
Phase
PHASE1
Sponsor
First Affiliated Hospital of Zhejiang University
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Romiplostim N01
  • Standard Supportive Care
Locations (sample)
  • Hangzhou, China|30.29365,120.16142

Key Eligibility Criteria

  • Patients with malignant hematologic diseases scheduled to undergo haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT) Ag…
  • Adequate hepatic function, defined as:Alanine aminotransferase (ALT) ≤2 × ULN.Aspartate aminotransferase (AST) ≤2 × ULN.Total bilirubin ≤1.5 × ULN.
  • Ability to understand and sign informed consent, and willingness to comply with all study requirements.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →